MACE, short for major adverse cardiovascular events, is a composite endpoint used in clinical trials that counts several serious outcomes as a single event, most often cardiovascular death, nonfatal heart attack and nonfatal stroke. It is not a test result and nothing a clinic can measure in you. It is a bookkeeping device for research: instead of asking separately whether a treatment prevents heart attacks, strokes and cardiac death, a trial asks whether it prevents any event on a pre-agreed list. Pooling rare outcomes into one count lets the study answer with fewer participants. The deeper clinical reference, including how the three-point and four-point versions differ, is the MACE — major adverse cardiovascular events entry in the Smart Longevity glossary.
What it measures
MACE measures how many people in each trial arm reached at least one event on the list, and how long that took. The list is fixed in the protocol before enrollment starts, and an independent blinded committee adjudicates every reported event against those definitions. The usual analysis is time to first event, so someone who has a heart attack and later dies of heart disease contributes one event, not two. It is normally run with a Cox proportional hazards model, and the headline result is a hazard ratio comparing treatment with control.
Which events count depends on the trial:
| Version | What it counts |
|---|---|
| Three-point MACE | Cardiovascular death, nonfatal myocardial infarction, nonfatal stroke |
| Four-point MACE | The three above plus one more, commonly hospitalization for unstable angina or heart failure, or urgent coronary revascularization |
| Expanded MACE | Broader lists adding any revascularization, hospitalization for any cardiovascular cause, or all-cause death instead of cardiovascular death |
There is no single agreed definition, and that is the central practical problem with the term. Nonfatal Myocardial infarction appears on essentially every version, but the fourth component and the choice between cardiovascular and all-cause death vary from protocol to protocol. Two trials can both report MACE while counting different things, which is why comparing a MACE number across trials is unreliable.
Why it matters for longevity
The events inside MACE end healthspan abruptly rather than gradually. Heart attack and stroke are leading causes of death worldwide and of long-term disability among survivors, so a therapy that shifts this endpoint changes how long people live well, not just how a lab panel reads. Most preventive treatments stand or fall on it.
Lowering a marker such as LDL cholesterol is a promise; lowering MACE in a randomized trial is evidence the promise was kept. The caution is that a composite hides its parts. Components differ enormously in severity, and the mildest, often a revascularization procedure, is usually the most frequent, so a treatment can move the total while leaving death and stroke untouched. Read the component breakdown under the headline, and the absolute difference in event rates rather than the relative reduction alone.
What changes it
You cannot change your own MACE, because it is a trial statistic rather than a personal measurement. What you can change is your underlying risk of the events it counts, and the levers are the familiar ones: not smoking, blood pressure control, lowering LDL cholesterol and apolipoprotein B, treating diabetes, regular aerobic and strength training, waist size, a mostly plant-based dietary pattern, and enough sleep.
Several have been tested against this exact endpoint. Statin trials reduced major vascular events roughly in proportion to how far LDL cholesterol fell and for how long, and blood pressure lowering reduced stroke and coronary events. In the PREDIMED trial a Mediterranean pattern with extra olive oil or nuts reduced major cardiovascular events, and in outcome trials of GLP-1 receptor agonists in people with type 2 diabetes or obesity plus established heart disease, three-point MACE was lower on treatment than on placebo. Your own risk is estimated with a risk score, not with MACE, and what to do about it belongs with your clinician.
Related reading
- Heart Health: A Prevention Guide for Longevity
- Weight-Loss Drugs Cut Cardiovascular Risk
- The Mediterranean Diet and Longevity: The Evidence
- Cardiovascular disease (CVD)
Disclaimer. This article is for information only and does not replace medical advice. Talk to a qualified clinician before changing anything about your health.